Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors
Cellectis SA (NASDAQ:CLLS) has announced four new preclinical UCART product candidates targeting solid tumors – UCART20x22; the first allogeneic bi-specific CAR-T…
Fusion Pharma’s Stock Moves Higher As Radiopharmaceutical Candidate Shows Early Promising Action In Solid Tumor Study
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) has announced preliminary Phase 1 data from the single-dose portion of the study evaluating FPI-1434 in patients…
Cerevel Therapeutics Announces Fast Track Designation Granted By The FDA To CVL-871 For The Treatment Of Dementia-Related Apathy
Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the U.S. Food and Drug Administration (FDA) has granted
Sage Therapeutics – Biogen’s Zuranolone Tops Placebo In Reducing Depressive Symptoms
Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major…
VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure
VectivBio Holding AG, (“Vectiv” or “VectivBio”) (NASDAQ:VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for
Ampio Stock Jumps On Enrollment Expansion Of Mid-Stage COVID-19 Trial To India With Inhaled Ampion
Ampio Pharmaceuticals Inc (NYSE:AMPE) has received regulatory approval to expand enrollment of its AP-019 Phase 2 study to India, assessing inhaled…
Clearside Biomedical Announces Safety Results From Cohort 1 Of OASIS Phase 1/2a Clinical Trial Of CLS-AX In Wet AMD; Primary Endpints In Cohort 1 Were Achieved
- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events -
- Initiating Cohort 2 patient screening for 0.1 mg dose in June 2021 -
ALPHARETTA, Ga., June
Autolus Therapeutics Receives Innovation Licensing and Access Pathway Designation From UK Medicines And Healthcare products Regulatory Agency For AUTO1
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway
FDA Authorizes ImmunityBio’s Study Of Anktiva And PD-L1 t-haNK To Increase Effectiveness Of Trodelvy In Triple-Negative Breast Cancer
Open-label Phase 1b/2 study will evaluate the safety and preliminary efficacy of Anktiva (N-803) and PD-L1 t-haNK in combination with antibody-drug conjugate Trodelvy and low-dose chemotherapy in subjects
VBL Therapeutics Says Was Notified By FDA That Clearance For New VB-111 Batches Is Pending Completion Of A Technical Review; Co. Expects Shortage Of Study Drug Supply for US And Has Paused Patient Recruitment
VBL Therapeutics (NASDAQ:VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer.
The Company was